Last reviewed · How we verify
L19TNF monothery in recurrent oligodendroglioma
L19TNF monothery in recurrent oligodendroglioma is a Biologic drug developed by Philogen S.p.A.. It is currently in Phase 2 development.
At a glance
| Generic name | L19TNF monothery in recurrent oligodendroglioma |
|---|---|
| Sponsor | Philogen S.p.A. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L19TNF monothery in recurrent oligodendroglioma CI brief — competitive landscape report
- L19TNF monothery in recurrent oligodendroglioma updates RSS · CI watch RSS
- Philogen S.p.A. portfolio CI
Frequently asked questions about L19TNF monothery in recurrent oligodendroglioma
What is L19TNF monothery in recurrent oligodendroglioma?
L19TNF monothery in recurrent oligodendroglioma is a Biologic drug developed by Philogen S.p.A..
Who makes L19TNF monothery in recurrent oligodendroglioma?
L19TNF monothery in recurrent oligodendroglioma is developed by Philogen S.p.A. (see full Philogen S.p.A. pipeline at /company/philogen-s-p-a).
What development phase is L19TNF monothery in recurrent oligodendroglioma in?
L19TNF monothery in recurrent oligodendroglioma is in Phase 2.